Research team
RHAMM and BMI1 as attractive immunotherapeutic target antigens for the development and optimization of a clinical grade multi-antigenic dendritic cell vaccine against leukemia and myeloma.
Abstract
For hematological malignancies, such as acute myeloid leukemia (AML), there is a strong need for novel, well-tolerated adjuvant treatments able to control or prevent the frequent relapse that is associated with these diseases. A promising strategy is autologous immunotherapy, which aims to stimulate the patient's own immune system to destroy residual malignant cells. With this project we want to investigate in vitro the feasibility and potency of a dendritic cell vaccine loaded with mRNA which codes for various tumor antigens.Researcher(s)
- Promoter: Berneman Zwi
- Fellow: Willemen Yannick
Research team(s)
Project type(s)
- Research Project
RHAMM as an attractive immunotherapeutic target antigen for dendritic cell-based induction of T-cell immunity to leukemia and myeloma.
Abstract
We want to establish in this project the in vitro T-cell antigenicity of RHAMM when introduced into DC of patients with AML and MM. RHAMM will be introduced into the DC as messenger RNA by our in-house developed and widely recognized electroporation method ensuring effective antigen presentation to CD4+ and CD8+ Tcells.Researcher(s)
- Promoter: Berneman Zwi
- Fellow: Willemen Yannick
Research team(s)
Project type(s)
- Research Project